Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Opus Genetics Inc. is navigating 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are spread across 3 distinct examiners. The portfolio's activity spans 3 distinct art units, matching the count of examiners and pending actions. This parity suggests that each of the company's current legal challenges is being evaluated in a unique technical and personnel environment within the 3 distinct art units.
SONG, JIANFENG is the busiest examiner for this portfolio, currently overseeing 1 busiest examiner pending office action. This workload is 1 of the 3 pending office actions currently active for the company. The presence of 3 distinct art units indicates that the company's biotechnology filings are technically diverse. The lack of examiner overlap means the company must manage 3 separate relationships within the patent office simultaneously to address the pending matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SONG, JIANFENG | 1 | 56.3% | +33.2% |
| DAHLIN, HEATHER RAQUEL | 1 | 41.1% | +47.5% |
| MOU, LIYUAN | 1 | 42.9% | +59.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19190263 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | SONG, JIANFENG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18209783 | METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE | MOU, LIYUAN | 77d |
| 19190263 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | SONG, JIANFENG | — |
| 18556599 | METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULAR CONDITIONS | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1629 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19190263 | AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF | SONG, JIANFENG | 1613 | §102§103§112 | Non-Final OA | — | Pending | Apr 25, 2025 |
| 18556599 | METHODS AND COMPOSITIONS FOR TREATING MYDRIASIS, GLAUCOMA, AND OTHER OCULAR CONDITIONS | DAHLIN, HEATHER RAQUEL | 1629 | §103§112DP | Non-Final OA | — | Pending | Oct 20, 2023 |
| 18209783 | METHODS AND COMPOSITIONS FOR DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE TO IMPROVE VISUAL PERFORMANCE | MOU, LIYUAN | 1628 | §103§112DPOther | Non-Final OA | 77d | Pending | Jun 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial